Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial
Non-alcoholic steatohepatitis (NASH) is associated with increased risk of liver-related and cardiovascular morbidity and mortality. Given the complex pathophysiology of NASH, combining therapies with complementary mechanisms may be beneficial. This trial evaluated the safety and efficacy of semaglut...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Alkhouri, Naim [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2022 |
|---|
| Schlagwörter: |
|---|
| Umfang: |
12 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Identification of the antigenic region of - Abdelbaky, Hanan H. ELSEVIER, 2018, official journal of the European Association for the Study of the Liver, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:77 ; year:2022 ; number:3 ; pages:607-618 ; extent:12 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.jhep.2022.04.003 |
|---|
| Katalog-ID: |
ELV058599061 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV058599061 | ||
| 003 | DE-627 | ||
| 005 | 20230625010011.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 221103s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jhep.2022.04.003 |2 doi | |
| 028 | 5 | 2 | |a /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001867.pica |
| 035 | |a (DE-627)ELV058599061 | ||
| 035 | |a (ELSEVIER)S0168-8278(22)00235-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.44 |2 bkl | ||
| 100 | 1 | |a Alkhouri, Naim |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial |
| 264 | 1 | |c 2022 | |
| 300 | |a 12 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Non-alcoholic steatohepatitis (NASH) is associated with increased risk of liver-related and cardiovascular morbidity and mortality. Given the complex pathophysiology of NASH, combining therapies with complementary mechanisms may be beneficial. This trial evaluated the safety and efficacy of semaglutide, a glucagon-like peptide-1 receptor agonist, alone and in combination with the farnesoid X receptor agonist cilofexor and/or the acetyl-coenzyme A carboxylase inhibitor firsocostat in patients with NASH. | ||
| 650 | 7 | |a cilofexor |2 Elsevier | |
| 650 | 7 | |a fibrosis |2 Elsevier | |
| 650 | 7 | |a NASH |2 Elsevier | |
| 650 | 7 | |a semaglutide |2 Elsevier | |
| 650 | 7 | |a firsocostat |2 Elsevier | |
| 650 | 7 | |a non-alcoholic steatohepatitis |2 Elsevier | |
| 700 | 1 | |a Herring, Robert |4 oth | |
| 700 | 1 | |a Kabler, Heidi |4 oth | |
| 700 | 1 | |a Kayali, Zeid |4 oth | |
| 700 | 1 | |a Hassanein, Tarek |4 oth | |
| 700 | 1 | |a Kohli, Anita |4 oth | |
| 700 | 1 | |a Huss, Ryan S. |4 oth | |
| 700 | 1 | |a Zhu, Yanni |4 oth | |
| 700 | 1 | |a Billin, Andrew N. |4 oth | |
| 700 | 1 | |a Damgaard, Lars Holm |4 oth | |
| 700 | 1 | |a Buchholtz, Kristine |4 oth | |
| 700 | 1 | |a Kjær, Mette Skalshøi |4 oth | |
| 700 | 1 | |a Balendran, Clare |4 oth | |
| 700 | 1 | |a Myers, Robert P. |4 oth | |
| 700 | 1 | |a Loomba, Rohit |4 oth | |
| 700 | 1 | |a Noureddin, Mazen |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Abdelbaky, Hanan H. ELSEVIER |t Identification of the antigenic region of |d 2018 |d official journal of the European Association for the Study of the Liver |g Amsterdam [u.a.] |w (DE-627)ELV000433829 |
| 773 | 1 | 8 | |g volume:77 |g year:2022 |g number:3 |g pages:607-618 |g extent:12 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.jhep.2022.04.003 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.44 |j Parasitologie |x Medizin |q VZ |
| 951 | |a AR | ||
| 952 | |d 77 |j 2022 |e 3 |h 607-618 |g 12 | ||
| author_variant |
n a na |
|---|---|
| matchkey_str |
alkhourinaimherringrobertkablerheidikaya:2022----:aeynefccocmiainhrpwtsmguieioeoadiscsaiptetwtnnlooisethp |
| hierarchy_sort_str |
2022 |
| bklnumber |
44.44 |
| publishDate |
2022 |
| allfields |
10.1016/j.jhep.2022.04.003 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001867.pica (DE-627)ELV058599061 (ELSEVIER)S0168-8278(22)00235-5 DE-627 ger DE-627 rakwb eng 610 VZ 44.44 bkl Alkhouri, Naim verfasserin aut Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial 2022 12 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Non-alcoholic steatohepatitis (NASH) is associated with increased risk of liver-related and cardiovascular morbidity and mortality. Given the complex pathophysiology of NASH, combining therapies with complementary mechanisms may be beneficial. This trial evaluated the safety and efficacy of semaglutide, a glucagon-like peptide-1 receptor agonist, alone and in combination with the farnesoid X receptor agonist cilofexor and/or the acetyl-coenzyme A carboxylase inhibitor firsocostat in patients with NASH. cilofexor Elsevier fibrosis Elsevier NASH Elsevier semaglutide Elsevier firsocostat Elsevier non-alcoholic steatohepatitis Elsevier Herring, Robert oth Kabler, Heidi oth Kayali, Zeid oth Hassanein, Tarek oth Kohli, Anita oth Huss, Ryan S. oth Zhu, Yanni oth Billin, Andrew N. oth Damgaard, Lars Holm oth Buchholtz, Kristine oth Kjær, Mette Skalshøi oth Balendran, Clare oth Myers, Robert P. oth Loomba, Rohit oth Noureddin, Mazen oth Enthalten in Elsevier Science Abdelbaky, Hanan H. ELSEVIER Identification of the antigenic region of 2018 official journal of the European Association for the Study of the Liver Amsterdam [u.a.] (DE-627)ELV000433829 volume:77 year:2022 number:3 pages:607-618 extent:12 https://doi.org/10.1016/j.jhep.2022.04.003 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.44 Parasitologie Medizin VZ AR 77 2022 3 607-618 12 |
| spelling |
10.1016/j.jhep.2022.04.003 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001867.pica (DE-627)ELV058599061 (ELSEVIER)S0168-8278(22)00235-5 DE-627 ger DE-627 rakwb eng 610 VZ 44.44 bkl Alkhouri, Naim verfasserin aut Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial 2022 12 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Non-alcoholic steatohepatitis (NASH) is associated with increased risk of liver-related and cardiovascular morbidity and mortality. Given the complex pathophysiology of NASH, combining therapies with complementary mechanisms may be beneficial. This trial evaluated the safety and efficacy of semaglutide, a glucagon-like peptide-1 receptor agonist, alone and in combination with the farnesoid X receptor agonist cilofexor and/or the acetyl-coenzyme A carboxylase inhibitor firsocostat in patients with NASH. cilofexor Elsevier fibrosis Elsevier NASH Elsevier semaglutide Elsevier firsocostat Elsevier non-alcoholic steatohepatitis Elsevier Herring, Robert oth Kabler, Heidi oth Kayali, Zeid oth Hassanein, Tarek oth Kohli, Anita oth Huss, Ryan S. oth Zhu, Yanni oth Billin, Andrew N. oth Damgaard, Lars Holm oth Buchholtz, Kristine oth Kjær, Mette Skalshøi oth Balendran, Clare oth Myers, Robert P. oth Loomba, Rohit oth Noureddin, Mazen oth Enthalten in Elsevier Science Abdelbaky, Hanan H. ELSEVIER Identification of the antigenic region of 2018 official journal of the European Association for the Study of the Liver Amsterdam [u.a.] (DE-627)ELV000433829 volume:77 year:2022 number:3 pages:607-618 extent:12 https://doi.org/10.1016/j.jhep.2022.04.003 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.44 Parasitologie Medizin VZ AR 77 2022 3 607-618 12 |
| allfields_unstemmed |
10.1016/j.jhep.2022.04.003 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001867.pica (DE-627)ELV058599061 (ELSEVIER)S0168-8278(22)00235-5 DE-627 ger DE-627 rakwb eng 610 VZ 44.44 bkl Alkhouri, Naim verfasserin aut Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial 2022 12 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Non-alcoholic steatohepatitis (NASH) is associated with increased risk of liver-related and cardiovascular morbidity and mortality. Given the complex pathophysiology of NASH, combining therapies with complementary mechanisms may be beneficial. This trial evaluated the safety and efficacy of semaglutide, a glucagon-like peptide-1 receptor agonist, alone and in combination with the farnesoid X receptor agonist cilofexor and/or the acetyl-coenzyme A carboxylase inhibitor firsocostat in patients with NASH. cilofexor Elsevier fibrosis Elsevier NASH Elsevier semaglutide Elsevier firsocostat Elsevier non-alcoholic steatohepatitis Elsevier Herring, Robert oth Kabler, Heidi oth Kayali, Zeid oth Hassanein, Tarek oth Kohli, Anita oth Huss, Ryan S. oth Zhu, Yanni oth Billin, Andrew N. oth Damgaard, Lars Holm oth Buchholtz, Kristine oth Kjær, Mette Skalshøi oth Balendran, Clare oth Myers, Robert P. oth Loomba, Rohit oth Noureddin, Mazen oth Enthalten in Elsevier Science Abdelbaky, Hanan H. ELSEVIER Identification of the antigenic region of 2018 official journal of the European Association for the Study of the Liver Amsterdam [u.a.] (DE-627)ELV000433829 volume:77 year:2022 number:3 pages:607-618 extent:12 https://doi.org/10.1016/j.jhep.2022.04.003 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.44 Parasitologie Medizin VZ AR 77 2022 3 607-618 12 |
| allfieldsGer |
10.1016/j.jhep.2022.04.003 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001867.pica (DE-627)ELV058599061 (ELSEVIER)S0168-8278(22)00235-5 DE-627 ger DE-627 rakwb eng 610 VZ 44.44 bkl Alkhouri, Naim verfasserin aut Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial 2022 12 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Non-alcoholic steatohepatitis (NASH) is associated with increased risk of liver-related and cardiovascular morbidity and mortality. Given the complex pathophysiology of NASH, combining therapies with complementary mechanisms may be beneficial. This trial evaluated the safety and efficacy of semaglutide, a glucagon-like peptide-1 receptor agonist, alone and in combination with the farnesoid X receptor agonist cilofexor and/or the acetyl-coenzyme A carboxylase inhibitor firsocostat in patients with NASH. cilofexor Elsevier fibrosis Elsevier NASH Elsevier semaglutide Elsevier firsocostat Elsevier non-alcoholic steatohepatitis Elsevier Herring, Robert oth Kabler, Heidi oth Kayali, Zeid oth Hassanein, Tarek oth Kohli, Anita oth Huss, Ryan S. oth Zhu, Yanni oth Billin, Andrew N. oth Damgaard, Lars Holm oth Buchholtz, Kristine oth Kjær, Mette Skalshøi oth Balendran, Clare oth Myers, Robert P. oth Loomba, Rohit oth Noureddin, Mazen oth Enthalten in Elsevier Science Abdelbaky, Hanan H. ELSEVIER Identification of the antigenic region of 2018 official journal of the European Association for the Study of the Liver Amsterdam [u.a.] (DE-627)ELV000433829 volume:77 year:2022 number:3 pages:607-618 extent:12 https://doi.org/10.1016/j.jhep.2022.04.003 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.44 Parasitologie Medizin VZ AR 77 2022 3 607-618 12 |
| allfieldsSound |
10.1016/j.jhep.2022.04.003 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001867.pica (DE-627)ELV058599061 (ELSEVIER)S0168-8278(22)00235-5 DE-627 ger DE-627 rakwb eng 610 VZ 44.44 bkl Alkhouri, Naim verfasserin aut Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial 2022 12 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Non-alcoholic steatohepatitis (NASH) is associated with increased risk of liver-related and cardiovascular morbidity and mortality. Given the complex pathophysiology of NASH, combining therapies with complementary mechanisms may be beneficial. This trial evaluated the safety and efficacy of semaglutide, a glucagon-like peptide-1 receptor agonist, alone and in combination with the farnesoid X receptor agonist cilofexor and/or the acetyl-coenzyme A carboxylase inhibitor firsocostat in patients with NASH. cilofexor Elsevier fibrosis Elsevier NASH Elsevier semaglutide Elsevier firsocostat Elsevier non-alcoholic steatohepatitis Elsevier Herring, Robert oth Kabler, Heidi oth Kayali, Zeid oth Hassanein, Tarek oth Kohli, Anita oth Huss, Ryan S. oth Zhu, Yanni oth Billin, Andrew N. oth Damgaard, Lars Holm oth Buchholtz, Kristine oth Kjær, Mette Skalshøi oth Balendran, Clare oth Myers, Robert P. oth Loomba, Rohit oth Noureddin, Mazen oth Enthalten in Elsevier Science Abdelbaky, Hanan H. ELSEVIER Identification of the antigenic region of 2018 official journal of the European Association for the Study of the Liver Amsterdam [u.a.] (DE-627)ELV000433829 volume:77 year:2022 number:3 pages:607-618 extent:12 https://doi.org/10.1016/j.jhep.2022.04.003 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.44 Parasitologie Medizin VZ AR 77 2022 3 607-618 12 |
| language |
English |
| source |
Enthalten in Identification of the antigenic region of Amsterdam [u.a.] volume:77 year:2022 number:3 pages:607-618 extent:12 |
| sourceStr |
Enthalten in Identification of the antigenic region of Amsterdam [u.a.] volume:77 year:2022 number:3 pages:607-618 extent:12 |
| format_phy_str_mv |
Article |
| bklname |
Parasitologie |
| institution |
findex.gbv.de |
| topic_facet |
cilofexor fibrosis NASH semaglutide firsocostat non-alcoholic steatohepatitis |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Identification of the antigenic region of |
| authorswithroles_txt_mv |
Alkhouri, Naim @@aut@@ Herring, Robert @@oth@@ Kabler, Heidi @@oth@@ Kayali, Zeid @@oth@@ Hassanein, Tarek @@oth@@ Kohli, Anita @@oth@@ Huss, Ryan S. @@oth@@ Zhu, Yanni @@oth@@ Billin, Andrew N. @@oth@@ Damgaard, Lars Holm @@oth@@ Buchholtz, Kristine @@oth@@ Kjær, Mette Skalshøi @@oth@@ Balendran, Clare @@oth@@ Myers, Robert P. @@oth@@ Loomba, Rohit @@oth@@ Noureddin, Mazen @@oth@@ |
| publishDateDaySort_date |
2022-01-01T00:00:00Z |
| hierarchy_top_id |
ELV000433829 |
| dewey-sort |
3610 |
| id |
ELV058599061 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV058599061</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625010011.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">221103s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jhep.2022.04.003</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001867.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV058599061</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0168-8278(22)00235-5</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.44</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Alkhouri, Naim</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">12</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Non-alcoholic steatohepatitis (NASH) is associated with increased risk of liver-related and cardiovascular morbidity and mortality. Given the complex pathophysiology of NASH, combining therapies with complementary mechanisms may be beneficial. This trial evaluated the safety and efficacy of semaglutide, a glucagon-like peptide-1 receptor agonist, alone and in combination with the farnesoid X receptor agonist cilofexor and/or the acetyl-coenzyme A carboxylase inhibitor firsocostat in patients with NASH.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">cilofexor</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">fibrosis</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">NASH</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">semaglutide</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">firsocostat</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">non-alcoholic steatohepatitis</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Herring, Robert</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kabler, Heidi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kayali, Zeid</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hassanein, Tarek</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kohli, Anita</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Huss, Ryan S.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zhu, Yanni</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Billin, Andrew N.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Damgaard, Lars Holm</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Buchholtz, Kristine</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kjær, Mette Skalshøi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Balendran, Clare</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Myers, Robert P.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Loomba, Rohit</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Noureddin, Mazen</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Abdelbaky, Hanan H. ELSEVIER</subfield><subfield code="t">Identification of the antigenic region of</subfield><subfield code="d">2018</subfield><subfield code="d">official journal of the European Association for the Study of the Liver</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV000433829</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:77</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:3</subfield><subfield code="g">pages:607-618</subfield><subfield code="g">extent:12</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.jhep.2022.04.003</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.44</subfield><subfield code="j">Parasitologie</subfield><subfield code="x">Medizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">77</subfield><subfield code="j">2022</subfield><subfield code="e">3</subfield><subfield code="h">607-618</subfield><subfield code="g">12</subfield></datafield></record></collection>
|
| author |
Alkhouri, Naim |
| spellingShingle |
Alkhouri, Naim ddc 610 bkl 44.44 Elsevier cilofexor Elsevier fibrosis Elsevier NASH Elsevier semaglutide Elsevier firsocostat Elsevier non-alcoholic steatohepatitis Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial |
| authorStr |
Alkhouri, Naim |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV000433829 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 VZ 44.44 bkl Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial cilofexor Elsevier fibrosis Elsevier NASH Elsevier semaglutide Elsevier firsocostat Elsevier non-alcoholic steatohepatitis Elsevier |
| topic |
ddc 610 bkl 44.44 Elsevier cilofexor Elsevier fibrosis Elsevier NASH Elsevier semaglutide Elsevier firsocostat Elsevier non-alcoholic steatohepatitis |
| topic_unstemmed |
ddc 610 bkl 44.44 Elsevier cilofexor Elsevier fibrosis Elsevier NASH Elsevier semaglutide Elsevier firsocostat Elsevier non-alcoholic steatohepatitis |
| topic_browse |
ddc 610 bkl 44.44 Elsevier cilofexor Elsevier fibrosis Elsevier NASH Elsevier semaglutide Elsevier firsocostat Elsevier non-alcoholic steatohepatitis |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
r h rh h k hk z k zk t h th a k ak r s h rs rsh y z yz a n b an anb l h d lh lhd k b kb m s k ms msk c b cb r p m rp rpm r l rl m n mn |
| hierarchy_parent_title |
Identification of the antigenic region of |
| hierarchy_parent_id |
ELV000433829 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
Identification of the antigenic region of |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV000433829 |
| title |
Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial |
| ctrlnum |
(DE-627)ELV058599061 (ELSEVIER)S0168-8278(22)00235-5 |
| title_full |
Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial |
| author_sort |
Alkhouri, Naim |
| journal |
Identification of the antigenic region of |
| journalStr |
Identification of the antigenic region of |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2022 |
| contenttype_str_mv |
zzz |
| container_start_page |
607 |
| author_browse |
Alkhouri, Naim |
| container_volume |
77 |
| physical |
12 |
| class |
610 VZ 44.44 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Alkhouri, Naim |
| doi_str_mv |
10.1016/j.jhep.2022.04.003 |
| dewey-full |
610 |
| title_sort |
safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: a randomised, open-label phase ii trial |
| title_auth |
Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial |
| abstract |
Non-alcoholic steatohepatitis (NASH) is associated with increased risk of liver-related and cardiovascular morbidity and mortality. Given the complex pathophysiology of NASH, combining therapies with complementary mechanisms may be beneficial. This trial evaluated the safety and efficacy of semaglutide, a glucagon-like peptide-1 receptor agonist, alone and in combination with the farnesoid X receptor agonist cilofexor and/or the acetyl-coenzyme A carboxylase inhibitor firsocostat in patients with NASH. |
| abstractGer |
Non-alcoholic steatohepatitis (NASH) is associated with increased risk of liver-related and cardiovascular morbidity and mortality. Given the complex pathophysiology of NASH, combining therapies with complementary mechanisms may be beneficial. This trial evaluated the safety and efficacy of semaglutide, a glucagon-like peptide-1 receptor agonist, alone and in combination with the farnesoid X receptor agonist cilofexor and/or the acetyl-coenzyme A carboxylase inhibitor firsocostat in patients with NASH. |
| abstract_unstemmed |
Non-alcoholic steatohepatitis (NASH) is associated with increased risk of liver-related and cardiovascular morbidity and mortality. Given the complex pathophysiology of NASH, combining therapies with complementary mechanisms may be beneficial. This trial evaluated the safety and efficacy of semaglutide, a glucagon-like peptide-1 receptor agonist, alone and in combination with the farnesoid X receptor agonist cilofexor and/or the acetyl-coenzyme A carboxylase inhibitor firsocostat in patients with NASH. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA |
| container_issue |
3 |
| title_short |
Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial |
| url |
https://doi.org/10.1016/j.jhep.2022.04.003 |
| remote_bool |
true |
| author2 |
Herring, Robert Kabler, Heidi Kayali, Zeid Hassanein, Tarek Kohli, Anita Huss, Ryan S. Zhu, Yanni Billin, Andrew N. Damgaard, Lars Holm Buchholtz, Kristine Kjær, Mette Skalshøi Balendran, Clare Myers, Robert P. Loomba, Rohit Noureddin, Mazen |
| author2Str |
Herring, Robert Kabler, Heidi Kayali, Zeid Hassanein, Tarek Kohli, Anita Huss, Ryan S. Zhu, Yanni Billin, Andrew N. Damgaard, Lars Holm Buchholtz, Kristine Kjær, Mette Skalshøi Balendran, Clare Myers, Robert P. Loomba, Rohit Noureddin, Mazen |
| ppnlink |
ELV000433829 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth |
| doi_str |
10.1016/j.jhep.2022.04.003 |
| up_date |
2024-07-06T19:30:07.611Z |
| _version_ |
1803859219040960512 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV058599061</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625010011.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">221103s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jhep.2022.04.003</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001867.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV058599061</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0168-8278(22)00235-5</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.44</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Alkhouri, Naim</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">12</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Non-alcoholic steatohepatitis (NASH) is associated with increased risk of liver-related and cardiovascular morbidity and mortality. Given the complex pathophysiology of NASH, combining therapies with complementary mechanisms may be beneficial. This trial evaluated the safety and efficacy of semaglutide, a glucagon-like peptide-1 receptor agonist, alone and in combination with the farnesoid X receptor agonist cilofexor and/or the acetyl-coenzyme A carboxylase inhibitor firsocostat in patients with NASH.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">cilofexor</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">fibrosis</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">NASH</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">semaglutide</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">firsocostat</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">non-alcoholic steatohepatitis</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Herring, Robert</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kabler, Heidi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kayali, Zeid</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hassanein, Tarek</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kohli, Anita</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Huss, Ryan S.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zhu, Yanni</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Billin, Andrew N.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Damgaard, Lars Holm</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Buchholtz, Kristine</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kjær, Mette Skalshøi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Balendran, Clare</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Myers, Robert P.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Loomba, Rohit</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Noureddin, Mazen</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Abdelbaky, Hanan H. ELSEVIER</subfield><subfield code="t">Identification of the antigenic region of</subfield><subfield code="d">2018</subfield><subfield code="d">official journal of the European Association for the Study of the Liver</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV000433829</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:77</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:3</subfield><subfield code="g">pages:607-618</subfield><subfield code="g">extent:12</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.jhep.2022.04.003</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.44</subfield><subfield code="j">Parasitologie</subfield><subfield code="x">Medizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">77</subfield><subfield code="j">2022</subfield><subfield code="e">3</subfield><subfield code="h">607-618</subfield><subfield code="g">12</subfield></datafield></record></collection>
|
| score |
7.39933 |